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1. Introduction 
The increasing population age, along with the prevalence of smoking and other 
environmental factors have contributed to a dramatic increase in the incidence of chronic 
pulmonary diseases with no known cures. Chronic obstructive pulmonary disease (COPD), 
lung cancer, and primary pulmonary hypertension are all conditions with well understood 
origins but few, if any therapeutic options. When taken in conjunction with the prevalence 
of genetic or poorly understood conditions such as cystic fibrosis (CF) and idiopathic 
pulmonary fibrosis (IPF) there is a large and growing cohort of patients that will eventually 
enter end-stage lung disease. The only currently available treatment option is lung 
transplantation which may potentially be extremely beneficial in terms of quality of life and 
life expectancy, although carries with it a vast array of considerations and complications. 
This chapter attempts to provide an account of the progress made in lung transplantation, 
complications associated with the procedure, current treatment for transplant associated 
conditions, and finally will discuss current research and possible future therapeutics.  
2. History of lung transplantation 
Lung transplantation remains the final therapeutic option for treatment of patients with 
diverse diagnoses of end stage lung disease. (Arcasoy and Kotloff 1999) This however, has 
not always been the case. It was only within the last three decades that the medical 
community achieved reproducible outcomes that translated into clinical improvement in the 
condition of the patient. Vladimir Demikhov is considered by some to be the founder of the 
field due to his work in animal models in the mid 20th century, but it wasn’t until 1963 that 
the first attempt at human lung transplantation occurred. (Cooper 1969; Hardy et al. 1963) 
This early trial was in a prisoner with both terminal lung cancer, and severe emphysema. 
Unfortunately, the patient died a mere 18 days post-transplantation. (Cooper 1969) It was 
almost another two decades before the first successful heart-lung transplantation was 
performed resulting in the multi-year survival of the recipient. This 1981 triumph was 
followed up by a group out of Toronto that proved once and for all that the one-time pipe 
dream of regular lung transplantation in humans was, in fact, a reality. (Cooper et al. 1987) 
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It was in the early 1990s that a comparative “transplant boom” began and has since leveled 
off to the approximately 2,700/year lung transplants performed worldwide today. (Orens 
and Garrity 2009) The relatively limited number (compared to other whole organ transplant 
procedures) of lung transplantations is a factor of limited supply of acceptable organs and 
ability to procure donor tissue. (Dilling and Glanville 2011) Unfortunately, it is because of 
this dearth of patients that few multi-center trials have been performed to assist in the 
investigation of better pre-, peri-, and post-operative techniques. However, with the increase 
in surgeries seen in the 1990s, serious efforts at reducing the risk factors associated with 
lung transplantation were initiated. 
3. Selection of candidates 
The majority of this chapter will deal with the complications and efforts to reduce them 
post-transplantation, but we will briefly touch on steps that have been implemented to 
reduce risk exposure prior to surgery. These preventative steps begin with a strict limitation 
on those who are eligible for transplant. Typically, individuals 55 and older are considered 
unsuitable for operation; although the mean age of recipients has been steadily increasing (it 
is currently over 50). (Dilling and Glanville 2011) Multiple organ failure, history of non-
compliance, active/recent cigarette smoking, and active cancer are all contraindications for 
enrolling a patient in the United Network for Organ Sharing (UNOS). (Maurer et al. 1998) 
One of the most important factors that clinicians must consider when evaluating a patient 
for transplantation is the infection state of the possible recipient. While most bacterial 
and/or viral colonizations are permissible, there are many transplant centers that refuse to 
operate on patients with unremitting infection with pan-resistant P. aeruginosa and B. cepacia.  
Even so, there is at least one group out of Canada that is willing to consider transplantation 
of this patient population. (Nash et al. 2010; Flume et al. 1994) Prior to 2005, the allocation of 
lungs in the United States was dependant solely on waiting time; those who had been on the 
list longer were given priority over newly enrolled patients. Unfortunately, this obviously 
created a selection bias against the acutely ill. In 2005 the Lung Allocation System 
underwent an overhaul, utilizing a Lung Allocation Score (LAS) to determine those patients 
that were both most in need of transplantation, and most likely to survive the surgery and 
excel in recovery. (Egan et al. 2006) The new LAS system includes a number of factors (age, 
6 minute walk test, forced vital capacity (FVC), body mass index (BMI), etc) to determine the 
patient’s predicted waitlist survival time. The LAS is equal to (Calculated 1 year survival 
benefit) – (Calculated 1 year waiting list survival). (Morton and Glanville 2009) Obviously, 
there are limitations to this type of allocation system; certain subjective metrics like 
functional status and diagnosis can affect the patient’s LAS, but the new method of lung 
allocation appears to have had a beneficial effect on median survival time post-
transplantation.  
4. Selection of donor organs 
4.1 Blood group matching and CMV status 
All of the evaluations discussed above are recipient-focused mechanisms designed to 
facilitate better outcomes in lung transplantation, but perhaps some of the most important 
protocols in place are related to obtaining the most viable donor organ available. There are 
several factors that contribute to the difficulty of procuring optimal lungs. Due to the 
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extremely limited time that lungs are able to endure ischemia (less than 6 hours), there is 
little opportunity to perform traditional human leukocyte antigen (HLA) matching. 
Physicians face an unfortunate catch-22; better HLA matching reduces incidence of chronic 
rejection, but increased ischemic time in turn leads to a higher propensity for rejection. 
(Brugiere et al. 2008) Blood groups, rather, are the primary method of histological matching, 
with consideration being given to size and cytomegalovirus (CMV) sero-status. However, 
this is somewhat disputed in a review of the heart-lung transplant patient population at 
Stanford. (Deuse et al. 2010) CMV sero-negative recipients are at a higher risk of developing 
CMV infection when miss-matched with sero-positive donors than those recipients that are 
already CMV sero-positive. CMV infection has shown to be immunomodulative; creating an 
increased risk of acute and chronic rejection, and infections. (Freeman 2009) Like other 
opportunistic infections, there is an increased risk of CMV disease with the use of 
immunosuppressive treatment, although CMV in turn increases the risk of rejection, 
defeating the intent of the immunosuppressive therapies. (Fishman et al. 2007) CMV 
infection is not only limited to lung transplant recipients and thus there have been 
significant efforts from all corners to establish a gold-standard of prevention and treatment 
for CMV disease in all transplant patients. In studies performed in kidney and liver 
recipients, investigators demonstrated a significant reduction in incidence of CMV disease 
and viremia, along with significant reduction in the number of opportunistic infections in 
patients treated with prophylactic valganciclovir. (Humar et al. 2010) Valganciclovir is 
currently considered the gold-standard in CMV prevention, but other DNA polymerase 
inhibitors, including ganciclovir and valacyclovir have been in use for several years with a 
smaller impact. (Zamora et al. 2004) Unfortunately, lung transplant recipients face a higher 
incidence of CMV infection than any other transplant patient population. This is for two 
primary reasons; first, CMV dormancy and recurrence have been shown to be higher in the 
lungs than anywhere else, and, unlike other whole organ transplant surgeries, there is a 
preponderance of lymphatic tissue transplanted with the lungs that contains further 
amounts of dormant virus. (Zamora, Davis, and Leonard 2005) 
4.2 Other donor factors 
Although blood group matching and CMV sero-status are two of the most important criteria 
when evaluating potential donor lungs, there are a multiple other factors surgeons must 
consider when assessing a possible donor organ. Traditionally it has been protocol to 
decline any lungs from donors positive for hepatitis B, even so, recent work has cracked 
open the door to this pool of donors, potentially increasing the donor pool and number of 
available organs. A 1-year longitudinal study showed no significant difference in survival of 
hepatitis B positive donor lung recipients compared to the hepatitis B sero-negative group. 
(Dhillon et al. 2009) The physicians must also take into account something as simple as time 
and distance when determining the possibility of performing the potentially life-altering 
operation. Lungs, like any other tissue, are susceptible to ischemia-reperfusion (IR) injury 
and the flood of damaging cytokines that go along with it. Primary graft dysfunction, which 
can occur in up to 20% of patients, has been directly attributed to IR injury. (Christie, Sager 
et al. 2005) In addition to this, the lungs are more readily affected by the abundance of fluids 
that are typically given in end of life situations. (Arcasoy and Kotloff 1999) Current thinking 
is that non-heart beating donors (NHBD) are ill suited for the harvesting of lungs due to the 
perceived damage that warm extended periods of ischemia would incur. This has been 
challenged, however by a group in Canada demonstrating no ill-adverse effects from the use 
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of this here-to-for off-limits pool of potential donor candidates. They state that there is an 
ameliorative effect on the levels of inflammatory cytokines present in these lungs which off 
sets the perceived ischemic damage. (Cypel et al. 2009)  
Donor age is another consideration that is factored in when considering possible 
transplantation. Not surprisingly, elevated donor age and increased ischemic times correlate 
with worse outcomes in transplant recipients. (Meyers and Patterson 2000) While not 
optimal, there is such a shortage of available donors, NHBDs over the age of 60 now 
represent over 10% of the NHBD donor population. (Ojo et al. 1999) There are several 
techniques available to try and optimize the donor lung, but most common are the use of 
vasopressin, and thyroid hormone. (Botha et al. 2008) Finally, brain dead (BD) donors 
represent a potential donor pool that presents its own unique set of possible complications. 
In animal models of BD, investigators observed a three fold increase in the blood volume in 
the pulmonary circulation within minutes after onset of BD. (Avlonitis et al. 2005) This, in 
concert with loss of sympathetic tone, contributes heavily to a rapid onset of pulmonary 
edema which in and of itself is enough to dissuade many surgeons from considering using the 
tissue. Furthermore, several groups have reported a significant increase in the concentrations 
of pro-inflammatory cytokines such as interleukin-1 (IL-1), IL-2, IL-6, and tumor necrosis 
factor-alpha (TNFα). (Skrabal et al. 2005; Pratschke et al. 2000; Shohami et al. 1994) 
Additionally, the neutrophil chemokine, IL-8, has also been demonstrated to be elevated in the 
lungs of BD lung donors. (Fisher et al. 1999) Increased neutrophil burden has been strongly 
associated with increased matrix-metalloprotease activity and possible exposure of the auto-
antigen collagen V (Coll V). (Fisher et al. 2001; Hardison 2009) The exposure of Coll V directly 
correlates with the incidence of primary graft dysfunction. (Iwata et al. 2008)  
All of the considerations discussed contribute to the limited number of lung transplants that 
are performed each year, but the lack of family consent is by far the largest obstacle to 
available donor organs. (Spital 2005) Since it is unlikely that an automatic-enrollment system 
similar to other countries is likely, it is vital that the best efforts are made to elucidate the 
mechanisms behind the numerous and varied complications inherent in lung 
transplantation by both basic scientists and clinicians alike. The litany of assessments and 
interventions discussed thus far are all employed to attempt to prevent the plethora of post-
transplantation complications that can arise. The unfortunate reality is that while surgical 
techniques and medical therapeutics are far more advanced and elegant than when the 
initial forays in lung transplantation occurred, there is still ample room for improving the 
outcomes observed in lung transplant recipients. The remainder of this chapter will discuss 
post-transplantation complications, current therapies, recent research in the field, and the 
exciting possibilities for novel therapeutics that are on the horizon. 
5. Post transplantation complications 
Due to the myriad of risk factors associated with lung transplantation, it has one of the 
highest morbidity and mortality rates of any whole organ transplant procedure. (Trulock et 
al. 2007) Only recently has the mean survival time for transplant recipients risen to 5.7 years. 
(Ahmad, Shlobin, and Nathan 2011) There are four major causes of morbidity and mortality 
in all transplant recipients; primary allograft dysfunction, infection, acute rejection, and 
chronic rejection. These four primary causes are closely related; rather they exist on a 
spectrum with the incidence of chronic rejection (the most serious) rising with increasing 
occurrences of the PGD, infection and acute rejection.  
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5.1 Primary graft dysfunction 
5.1.1 Characterization and etiology 
Primary graft dysfunction (PGD) is defined as having a PaO2/Fi O2 of ≤ ~300 with 
radiographic infiltrates consistent with pulmonary edema. (Christie, Carby et al. 2005) PGD 
is further categorized into 3 gradations with Grades 1, 2 and 3 corresponding to PaO2/Fi O2 
greater than 300, between 200 and 300, and less than 200, respectively. Clinically, PGD is 
simply a unique form of acute lung injury (ALI), presenting within 72 hours post-surgery 
with replete pulmonary infiltrates/edema and impaired compliance. These guidelines for 
evaluating PGD were initially put forth in 2005 by the International Society for Heart and 
Lung Transplantation (ISHLT) Working Group on PGD and later confirmed by a 
retrospective study of approximately 400 lung transplant recipients. This study 
demonstrated that PGD grade 3 did indeed correlate with the worst mortality. (Prekker et 
al. 2006) PGD can affect up to 25% of patients and correlates with much higher levels of 
mortality in the first 30 days. (Christie et al. 2005) The precise cause(s) of PGD are still 
unknown, but it is widely accepted that ischemia-reperfusion (IR) injury plays a major role 
in initiating the destructive process. It is in the ischemic period that reactive oxygen species 
(ROS) are produced in large quantities and directly damage the pulmonary epithelium and 
endothelium. (Tasoulis et al. 2009; de Perrot et al. 2003) This influx of ROS incites a pro-
inflammatory cascade that activates both the innate and complement immune systems. 
(Carter, Gelman, and Kreisel 2008)  
5.1.2 Risk factors for PGD 
Advanced age of organ donors is strongly associated with increased incidence of PGD in 
lung transplant recipients. What is interesting is that no definitive studies have been 
performed that indicate that recipients’ age play any role in the development of PGD. (Barr 
et al. 2005; Christie et al. 2003) Additionally, race (African-American), sex (female), and 
smoking history are all donor-dependent risk factors in the development of PGD. (Lee and 
Christie 2009) No conclusive studies of transplant recipients have explicitly delineated 
whether indication for transplantation correlates with development but it appears that 
idiopathic pulmonary fibrosis confers at least some increased risk of PGD. (Barr et al. 2005) 
Pulmonary arterial hypertension (PAH) has emerged as the only clinically measureable 
metric that correlates with the development of primary graft dysfunction. While the precise 
pathway of PAH to PGD is as yet unknown, multiple studies have demonstrated the 
relationship. (Whitson et al. 2006)  
5.1.3 Treatment of PGD 
Although over-used to the point of being a cliché, the maxim “an ounce of prevention is 
worth a pound of cure” is distinctly applicable to the treatment of primary graft 
dysfunction. Increasing emphasis is being placed on improved preservation of the donor 
organ. The main weapon in the clinician’s arsenal of preservative techniques is induced 
hypothermia of the tissue. It has been demonstrated that by maintaining the organ at 4oC, 
the metabolic rate is drastically reduced compared to that of control temperature tissue. (de 
Perrot et al. 2005) Two methods of organ cooling are typically employed; core cooling and 
pulmonary arterial flush (PAF). (Okada and Kondo 2009) The core cooling method occurs 
prior to organ explantation and is initiated with cardio-pulmonary bypass to reduce the 
body temperature to ~14oC. Upon harvesting, the donor lungs are submerged in 4oC saline. 
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PAF is accomplished by instilling 60ml/kg into the pulmonary artery, there have been some 
recent studies investigating the effects of a dual flush with the addition of flushing the 
pulmonary veins as well. The hypothesis being that this would ensure the complete removal 
of micro-thrombi in the capillaries and result in a more equitable distribution of the 
preservative solution. (Struber et al. 2002) There are several different “recipes” of 
preservative solution but the first in wide use (Euro-Collins solution), with high a high K+ 
and low Na+ concentrations to mimic intracellular fluid, was originally developed for use in 
liver preservation. (Okada and Kondo 2009) Since then, more sophisticated preservation 
solutions have been developed and are in the process of being tested. The Okada group 
developed a solution termed extra-cellular phosphate buffered saline type 4 (Ep4) that 
included dextran 40. This solution was capable of preserving canine lungs for up to 96 hrs 
post-explantation. Dextran 40 appeared to exert an anti-coagulative effect, ostensibly by 
forming a protective coat on the endothelial surface. (Handa et al. 1989; Okada et al. 1997; 
Colombat et al. 2004)  
Sadly, if efforts to prevent the development of primary graft dysfunction fail, the similarity 
to acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) results in little 
that the clinician can do other than provide supportive care. Due to the increased 
concentration of pro-inflammatory cytokines in the pulmonary circulation it is of vital 
importance that fluid administration is closely monitored to decrease the risk of fulminant 
edema. (Shargall et al. 2005) In addition to the vigilance given to the administration of fluids 
in PGD patients, ventilator settings can play a major role in outcomes of those individuals. A 
multicenter, randomized, controlled trial demonstrated that lower tidal volumes, combined 
with elevated positive end expiratory pressure (PEEP) were significantly protective in 
individuals with ARDS. The authors of the study hypothesize that this was due to the 
decreased alveolar damage in the hyper-compliant lungs. (Petrucci and Iacovelli 2003)  
5.1.4 Current research and future directions 
Much of the current research in this area is focused on the development of better 
therapeutics and the identification of biomarkers in PGD to provide a deeper knowledge of 
the genetic and biochemical forces that are integral in the genesis of the condition. With the 
recent advances made in high through-put proteomics and DNA micro-array technology 
there are ample platforms to rapidly pursue numerous avenues of investigation in great 
detail. 
5.1.4.1 Potential Biomarkers of PGD 
A 2006 study by Kaneda et al, utilizing quantitative real time polymerase chain reaction 
(qPCR) revealed that the IL-6/IL-10 ratio in the donor lung was predictive of 30 day 
mortality in the transplant recipient. (Kaneda et al. 2006) Luminex analysis of blood samples 
from 25 Grade 3 PGD patients and 25 Grade 0 control patients by Hoffman, et al revealed a 
vastly different chemokine profile in the two population’s plasma. Severe PGD patients had 
significantly elevated levels of monocyte chemotactic protein-1 (MCP1) and CXC motif 
ligand 10 (CXCL10) compared to controls. (Hoffman et al. 2009) The detection of novel 
biomarkers is not limited to new sophisticated techniques, more traditional approaches also 
have also yielded results. Indeed, a recent study by Diamond, et al, using a conventional 
“sandwich” enzyme linked immunosorbent assay (ELISA) provided evidence that increased 
Clara cell secretory protein 16 (CC16) was significantly associated with the development of 
PGD. (Diamond et al. 2011) There are numerous other studies that have produced a litany of 
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possible biomarkers (soluble receptor for advanced glycosylation end-products (sRAGE), 
soluble P-selectin, Protein C, etc.) for primary graft dysfunction and that may one day 
provide the key to its early detection and prevention. (Kawut et al. 2009; Christie et al. 2007; 
Christie et al. 2009)  
5.1.4.2 Novel/Future Therapeutics for PGD 
The goal of those developing novel therapeutics for PGD is the prevention of the condition 
itself. A multi-center, randomized, placebo controlled trial by Keshavjee, et al showed a 
protective effect in the use of soluble complement receptor-1 (sCR1) resulting in decreased 
time to extubation and a trend toward abbreviated intensive care unit (ICU) stays. (Keshavjee 
et al. 2005) In an intriguing study by Eriksson, and colleagues, induced hypothermia appeared 
to be beneficial in case studies of PGD patients and was recapitulated in an animal model. 
(Eriksson and Steen 1998; Eriksson et al. 1999) Significant forays into the use of inhaled Nitric 
Oxide (iNO) as a therapeutic agent have also been made in recent years. There have been 
discordant results, however as to the efficacy, ranging from no change in outcomes to a 
decreased incidence of severe PGD and diminished concentrations of IL-6 and IL-8 in plasma 
compared to controls. (Meade et al. 2003; Ardehali et al. 2001) Due to the prevalence of PGD in 
lung transplant recipients, and the comparative lack of knowledge regarding the pathogenesis 
of this condition, it is reasonable to expect considerable resources to continue to be directed 
toward the investigation and prevention of this syndrome. 
5.2 Infection 
5.2.1 Characterization and etiology 
Infection in post lung transplantation begins as any other infection, however with the host 
being in the unenviable position of possessing immune systems under active and permanent 
suppression, in addition to the mechanical and physiologic stress that is inherent to any 
major surgery. Infection is, in fact, the primary source of mortality in the first year post-
transplant and continues to be a significant source of morbidity and mortality for the 
remainder of the recipient’s life. (Corris and Christie 2008) Unlike all other solid organ 
transplants, the lungs are open to the external environment and all of the pathogens, both 
virulent and opportunistic, that entails. Furthermore, the denervation that is a necessary 
component of organ harvesting results in at least a temporary impairment in the cough 
reflex and thus diminished clearance. (Ahmad, Shlobin, and Nathan 2011) It is important to 
note that any infection, particularly recurrent infection, is a risk factor for the occurrence of 
rejection, both acute and chronic. Rapid identification of the pathogen and appropriate 
treatment is optimal to decrease morbidity and mortality in this patient population. 
5.2.2 Bacterial infection 
Bacterial infections are the most common type of infection in lung transplant recipients and 
occur in a bi-modal, temporal-dependant manner. Pulmonary bacterial infections are 
common both early, due to the previously mentioned impaired cough reflex and damaged 
lymphatic system, and late, as an element of chronic rejection. (Kramer et al. 1993) Due to 
the nature of the pre-transplant disease, those patients with cystic fibrosis (CF) are the most 
difficult to maintain in an infection free state. This is especially true in the individual with a 
single lung transplant due to the potential for colonization from the native lung. 
Interestingly, the CF patient population also has the best long-term results despite the 
proclivity towards infection. (Lease and Zaas 2010)  
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Pseudomonas aeruginosa is the most common bacterial organism isolated from the post-
transplant lung. (Kramer et al. 1993) This opportunistic infection has a higher incidence in 
CF patients and has been estimated to be responsible for up to 33% of pneumonias in all 
transplant recipients. (Aguilar-Guisado et al. 2007; Campos et al. 2008) P. aeruginosa airway 
infection prior to transplant does not appear to demonstrate a predictive relationship for 
chronic rejection. However, this is not the case for colonization in the post-operative period. 
(Botha et al. 2008; Vos et al. 2008) P. aeruginosa infection is not limited to pneumonias; the 
pathogen has been reported to be responsible for nearly half of all post-transplant infections. 
(Valentine et al. 2008)  
Mycobacterium is a designation indicating acid-fast bacteria that are capable of causing a 
wide range of diseases. Perhaps the most well known of these M. tuberculosis, has the robust 
cell wall that is a calling card of the classification, and helps to confer resistance to broad 
spectrum antibiotics. Although, not nearly as common as P. aeruginosa infection, M. 
tuberculosis colonization presents a unique set of treatment hurdles, especially in the 
presence of multi-drug resistant (MDR) strains. (Lee et al. 2003)  
Opportunistic infections, hospital-acquired infections, and resistant strains of bacteria are all 
significantly more common in lung transplant recipients than the general population. 
Staphylococci strains have demonstrated a propensity for antibiotic resistance and this is only 
magnified in the already immunosuppressed transplant patient. Specifically, S. aureus is the 
second most common organism isolated from the airway, with multi-drug resistant S. aureus 
(MRSA) being extremely difficult to treat due to its almost pan-resistant nature. (Kotloff and 
Thabut 2011)  
5.2.3 Treatment of bacterial infection 
The treatment of infection in lung transplant recipients is a challenging task due to the 
patients’ significant cocktail of immunosuppressive therapies. Many of these drugs, 
including cyclosporine and tacrolimus can be highly cross-reactive. There is unfortunately 
no “magic bullet” specific for transplant patients, the traditional regimen of broad spectrum 
antibiotics, with specific coverage for gram negative, acid-fast, etc. being added upon 
differential diagnosis.  
5.2.4 Fungal infection 
While colonization by widespread fungi such as Aspergillus and Candida is common, a much 
smaller percentage of patients will develop a clinically relevant fungal infection. (Singh 
2003) Aspergillus and Candida are by far the most common, with Cryptococcus species and 
other molds playing a much smaller role. (Neofytos et al. 2010) The presence of foreign 
material (sutures) in the airway anastomosis, in addition to the inherent risk with 
ventilation, increases the risk of fungal infection in post-operative transplant patients.  
5.2.5 Prevention/treatment of fungal infection 
Similar to the treatment of bacterial infections, the therapeutic approach to fungal infection 
in lung transplant patients is primarily unchanged from the normal treatment options in 
other patients. Treatment regimens will typically consist of aerosolized Amphotericin B in 
the acute post-operative period, with voriconazole and itraconazole prophylactic treatment 
extending for up to a year post-transplantation. (Ahmad, Shlobin, and Nathan 2011)  
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5.2.6 Viral infection 
As has previously been mentioned, the sero-status of cytomegalovirus (CMV) is an 
important factor in opting to transplant or harvest donor organs. CMV is by far the most 
common viral pathogen observed after lung transplant procedures, affecting at least a third 
of all patients. CMV usually presents with fever, exhaustion, and flu-like symptoms with 
associated leukopenia. (Snydman et al. 2011) Diagnosis of CMV syndrome is made with 
PCR evaluation of viral titers in peripheral blood. If CMV pneumonia is suspected, the 
definitive test must be performed on a biopsy specimen of the in tissue. (Kotton et al. 2010) 
CMV infection has been shown to predispose the patient to infection with other community 
acquired respiratory viruses (CARVs). (Sims and Blumberg 2011) 
In a recent three year longitudinal study, Kumar et al showed the presence of virulent 
strains of H1N1 influenza, adenovirus, flu A, flu B, and rhinovirus in over half of transplant 
recipients. (Kumar et al. 2010) Diagnosis of these viral infections has become much more 
straightforward with the advent of qPCR to provide rapid evaluation of viral titer loads in 
bronchoalveolar lavage (BAL) fluid of patients. Antibody based assays are also available to 
determine the infection state of an individual, although these may vary from center to 
center.  
5.2.7 Prevention/treatment of viral infection 
Intravenous (IV) ganciclovir and the oral pro-drug valganciclovir are given prophylactically 
for anywhere from 6 to 12 months post-transplant. (Jaksch et al. 2009) CMV prophylaxis is 
standard protocol for all patients regardless of center and has been shown to be effective in 
reducing the CMV syndrome. (Palmer et al. 2010) Treatment for CARVs is dependant upon 
specific diagnosis of pathogen and strain and can include zanamivir, amantidine, 
oseltamivir, etc. (Ison and Michaels 2009) Unlike CMV therapy, prolonged treatment with 
these anti-virals is contraindicated for fear of contributing to the development of resistance. 
5.3 Acute rejection 
5.3.1 Characterization/etiology of acute rejection 
Acute rejection (AR) presents clinically with non-specific symptoms including dyspnea, 
mild fever, malaise, cough, and leukocytosis. Although not present in all AR exacerbations, 
radiographic imaging may show mild pleural effusion, and interstitial opacities with a 
concurrent decline in oxygenation and spirometric measurements. (Millet et al. 1989; 
Otulana et al. 1990) AR is definitively diagnosed by BAL and TBB followed by histological 
analysis showing perivascular infiltrates. (Stewart et al. 2007) TBB may not always be 
possible due to patient status and thus AR is tentatively determined based upon clinical 
symptoms and radiologic evidence. Many transplant centers have post-transplant protocols 
that include routine monitoring by BAL which is also capable of confirming AR. (Chakinala 
et al. 2004) Most importantly, as indicated by the name, acute rejection is just that, a brief 
intermittent condition that is most often easily resolved with or without hospitalization. 
Acute rejection is an extremely common complication of lung transplant patients, occurring 
in as many as 90% of lung recipients over their lifespan. (Arcasoy 2004) The incidence of AR 
is highest within the first year post-transplant, afflicting approximately one third of all 
patients. (Christie et al.) It is difficult to determine precise results in these retrospective 
studies due to the fact that AR can be clinically silent, only detectable upon transbronchiole 
biopsy (TBB). (Hopkins et al. 2002) The precise etiology of AR is still unknown but stratified 
risk appears to be heavily weighted toward donor-dependent factors in the immediate post-
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operative period, with recipient-dependent factors playing the predominant role after the 
first year. HLA-B mismatching, increasing donor age, non-O donor blood type, and 
increasing body-surface area (most likely corresponding to elevated BMI) all correspond 
with increased AR incidence. With a recipient history of diabetes, and recent transplant 
accounting for recipient driven risk in the intermediate and late phase AR. (Mangi et al. 
2011) 
The International Society for Heart-Lung Transplantation (ISHLT) has delineated the 
standard nomenclature to describe the various gradations of AR based solely on histological 
findings. Grade A0 is the absence of AR, no cellular infiltrates and healthy lung 
parenchyma. Grade A1 is characterized by patchy mononuclear cell infiltrates in alveolar 
parenchyma. Grade A2 is described as having more prevalent lymphocytic infiltrates 
centered in the perivascular area with the presence of some activated macrophages and 
eosinophils. Grade A3 features dense perivascular infiltrates, significant eosinophil 
presence, with the first observation of neutrophils in the intra-alveolar space. Grade A4 
describes the finding of diffuse mononuclear infiltrates, pneumocyte damage, macrophage 
and neutrophil presence. (Stewart et al. 2007)  
5.3.2 Treatment of acute rejection 
Similar to many aspects of lung transplantation, treatment for AR varies dependant upon 
hospital setting with some centers opting to not treat AR considered to be <Grade A2. 
(Orens and Garrity 2009) In more severe cases however, conventional treatment consists of a 
hospital admission with a three day course of solumedrol followed by an oral prednisone 
taper. (Aboyoun et al. 2001; Yousem et al. 1994) Additional treatment with methotrexate, 
lymphoid irradiation, and antithymocyte globulin, among others, has been reported to be 
effective in alleviating the transient AR condition. (Hachem 2009)  
5.3.3 Biomarkers of acute rejection 
Although ISHLT has defined acute rejection based solely upon histological findings, there is 
significant effort to describe biomarkers specific to patients undergoing AR to better classify 
and determine treatment. A recent study by a group out of Copenhagen described elevated 
mRNA of the regulatory T cell (Treg) cytokine FoxP3, along with cytotoxic T cell-derived 
granzyme B in BAL fluid of patients in AR. (Madsen et al. 2010) A 2007 study by Lande et al 
describes the use of microarray analysis to observe relative gene expression levels of 
cytokines thought in be involved in acute rejection in the BAL fluid of AR patients. (Lande 
et al. 2007) 
5.3.4 Novel/future therapeutics of acute rejection 
Due to the incredible amounts of data generated by high through methods such as mass-
spectrometry-assisted proteomics and gene microarray analysis there have never been more 
targets identified for the design of targeted therapeutics in acute rejection. The use of animal 
models of acute rejection have also significantly improved the ability to design and test 
novel therapeutics for acute rejection allograft rejection in lung transplantation. 
Jung et al (2006) have developed a spontaneous model of acute rejection in rats by 
performing lung transplantation in a manner similar to that used in humans. By utilizing a 
small molecule, irreversible inhibitor of dipeptidylpeptidase IV (DPPIV/CD26) the 
investigators reduced the incidence of acute rejection, preserved lung function, and 
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maintained normal histological structure in rat lung transplantees. (Jung et al. 2006) They 
previously published that DPPIV/CD26 was elevated in plasma of rats undergoing AR after 
cardiac transplant and hypothesize that the pulmonary protective effect is due to reducing 
the co-stimulatory effect of DPPIV/CD26 on T cells. (Korom et al. 1997) In a similar model, a 
group out of Fukouka, Japan employed a Janus kinase 3 (Jak3) inhibitor to prevent the 
development of AR. Jak3 is located at a biochemical bottleneck in the pathway of T cell 
clonal expansion. Higuchi, et al demonstrated a dose-dependant inhibition of the 
development of acute rejection by the AG490 in the experimental population. (Higuchi et al. 
2005) 
Animal models are not the only avenue available to scientists to pursue better methods of 
treating and preventing acute rejection. Investigators at the University Clinics of Leipzig 
reported a reduction in the incidence of acute rejection with preemptive administration of 
the traditional therapeutic methylprednisone. By simply giving bolus doses 2 hours prior to 
incision and immediately prior to completion of the transplant procedure they observed a 
significant improvement in outcomes. (Bittner et al. 2010) 
Clearly this is not meant to be an exhaustive review of the potential novel therapeutics 
currently under development. We are merely presenting a representative sample indicating 
the myriad of pathways that are being studied to yield targeted countermeasures to acute 
rejection. 
5.4 Chronic rejection (bronchiolitis obliterans syndrome) 
5.4.1 Characterization/etiology of bronchiolitis obliterans syndrome 
Chronic rejection, clinically termed bronchiolitis obliterans syndrome (BOS), is the primary 
source of morbidity and mortality seen in the lung transplant patient population. (Bando et 
al. 1995; Stewart et al. 2007) Due to the nature of BOS, primarily occurring irregularly in the 
small airways, diagnosis by transbronchial biopsy is ineffective. (Chamberlain et al. 1994) 
Diagnosis of BOS is difficult due to its similarities with other post-transplant complications. 
There are no tests to specifically determine BOS, rather, it is a diagnosis of exclusion. A 
persistent, unexplainable drop in forced expiratory volume in one second (FEV1) (~80% of 
baseline) with accompanying decline in FEV25-75 (less than or equal to 75% of baseline) is 
defined as BOS stage 0. (Belperio et al. 2009; Estenne et al. 2002) BOS is staged 0-3 based 
upon progressive declines in percent of expected FEV1.  
BOS is unfortunately observed in over half of lung transplant patients who survive five 
years or more post-transplantation. (Bando et al. 1995) Chronic rejection initially presents 
clinically in a manner similar to that of other complications with dyspnea, cough, and 
progressive airway obstruction. (Estenne and Hertz 2002) X-ray analysis is often 
unremarkable, but computer assisted tomography (CT) may reveal air trapping and 
bronchiectasis. (Morrish et al. 1991) 
BOS is characterized pathologically by a prominent neutrophilic component with a definite 
increase in pulmonary fibrosis and extra-cellular remodeling. (Billings et al. 2002; Boehler 
and Estenne 2003) The BAL fluid of the majority of BOS patients reveals chronic pulmonary 
neutrophilia. Indeed, when >20% of cells are neutrophils in BAL fluid patients fail to 
survive past 7 years post-transplant. (Neurohr et al. 2009) Unlike acute rejection, where the 
cellular infiltrates are centered around the vasculature, in BOS, the cells are located 
primarily in and around the airways with a striking increase in cell number and activation 
level of leukocytes. (Vanaudenaerde et al. 2008) The causes of BOS are only partially 
understood with much unknown about the exact causative events that lead to disease. 
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5.4.2 Risk Factors for bronchiolitis obliterans syndrome 
What facts are known about the pathogenesis of BOS are the multiple risk factors that have 
been detailed via epidemiologic investigations. Both alloimmune and alloimmune-
independent factors appear to play principle roles in the development of BOS. (Knoop and 
Estenne 2006) Primary graft dysfunction, along with gastroesophageal reflux (GER), and 
infection are all nonalloimmune factors that are associated with occurrence of BOS. (Estenne 
and Hertz 2002) CMV infection resulting in disease has been reported to enhance the 
relative risk of developing BOS, although there are conflicting reports regarding this. 
(Belperio et al. 2009) Alloimmune factors closely associated with BOS are recurrent, or 
persistent AR, and HLA mismatching. (Palmer et al. 2002) 
5.4.3 Treatment of bronchiolitis obliterans syndrome 
Currently there are no demonstrated effective treatments for BOS. Most present strategies 
rely on augmenting immunosuppression with the use of corticosteroids, cyclosporine, 
methotrexate, etc. (Date et al. 1998; Dusmet et al. 1996; Iacono et al. 1996) These, however 
have been met with little success. The majority of existing treatment methods rely on 
unproven, anecdotal evidence with few multi-center, randomized, controlled trials. 
5.4.4 Current research and future directions in bronchiolitis obliterans syndrome 
Our previously published hypothesis regarding the onset of BOS is that there is some initial 
insult (infection by CMV or other pathogens, inflammatory damage due to recurrent AR, 
etc.) that awakens the adaptive immune system to over-ride the potent cocktail of 
immunosuppressive drugs present. The adaptive immune (Type 1, and Type 2 T cells) 
further damages the transplanted organ by responding to the foreign epitopes innately 
present in the donor lung. This repeated damage induces a persistent release of pro-
inflammatory cytokines that recruit neutrophils into the interstitium and airways where 
they remain and participate in a fibroproliferative and proteolytically destructive process. 
(Hardison et al. 2009) 
5.4.4.1 Potential Biomarkers in Bronchiolitis Obliterans Syndrome 
We, along with others, have reported on the activation of neutrophils by glutamate-leucine-
arginine positive (ELR+) CXC chemokines such as IL-8. (Xu et al. 2011; Chakrabarti and 
Patel 2005) Upon activation, neutrophils degranulate which releases potent proteases such 
as matrix metalloproteinase-8, -9, and prolyl endopeptidase. (Xu 2011, O’Reilly 2010) It has 
been well established that collagen fragments are chemotactic to neutrophils, and in 1995, 
Pfister et al. were able to determine the sequence, proline-glycine-proline (Pro-Gly-Pro, 
PGP) confers chemotactic potential to collagen breakdown products. (Pfister et al. 1995) In a 
2006 paper, our group demonstrated the mechanism by which PGP is able to attract 
neutrophils into tissue. PGP shares significant sequence and structural homology with 
almost all ELR+CXC chemokines, which act via CXC receptors 1 and 2 in human (CXCR1, 
CXCR2). We reported that PGP competes with the CXCR ligand, IL-8, for binding, causes 
chemotaxis in CXCR transfected cells and elicits a similar oxidative burst to IL-8 stimulation. 
(Weathington et al. 2006) Recently we have also published the step-wise manner in which it 
is produced. (Gaggar et al. 2008)  
MMP-8 and -9 are capable of initially digesting collagen but are incapable of performing the 
final cleavage to PGP and a second step is necessary for the matrikine’s production. Our lab 
demonstrated that the serine protease prolyl endopeptidase (PE) performs the final 
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proteolysis. (Gaggar et al. 2008) PE cleaves after a proline in a peptide of ~100 amino acids 
or less.  
We have reported the potential for PGP as a biomarker of disease in multiple chronic 
inflammatory lung diseases such as cystic fibrosis (CF), chronic obstructive pulmonary 
disease (COPD), and most relevant to this manuscript, BOS. (Gaggar et al. 2007; O'Reilly et 
al. 2009; Hardison et al. 2009) In matched BAL samples of patients obtained three months 
prior to, and concurrent with diagnosis of BOS, we described a temporal shift in the 
chemokine/matrikine profile. MMP-8, -9 and PE activities were increased in the samples 
collected at diagnosis of BOS compared to a transplant control population, and matched 
samples collected prior to confirmation of disease. By employing a previously published 
mass spectrometry technique, we detected measureable amounts of PGP in both pre- and 
post-diagnosis of BOS, however, there was a dramatic and significant increase in the levels 
observed in BAL fluid collected at the time of diagnosis. Through the use of neutralizing 
antibodies to IL-8 and PGP, first individually and then in concert, we demonstrated a shift 
from the relative importance of the classical PMN chemoattractant, IL-8, to the more novel 
molecule, PGP, upon diagnosis of BOS.  
Clearly PGP is not the only molecule with the potential to serve as a novel biomarker for 
BOS diagnosis. There is a litany of research underway on a wide variety of proteins and cell 
types that may potentially one day play a role in the more precise classification of this 
condition. Endothelin-1, mesenchymal stromal cells, and serum KL-6 (a glycoprotein) have 
all been published as possible markers of disease progression. (Salama et al. 2011; Badri et 
al. 2011; Haberman et al. 2010) 
5.4.4.2 Current Research in Bronchiolitis Obliterans Syndrome 
Perhaps the most exciting development in the quest for reliable preventative therapy for 
BOS has been the recent establishment of reproducible rodent models of BOS which closely 
mimic human disease. The most recent model described by Jungraithmayr, et al., utilizing 
single lung transplantation, is a vast improvement over the traditional tracheal transplant 
which had the obvious limitation of leaving the native lung in the rodent. (Jungraithmayr et 
al. 2010) The Swiss group reports that a T cell response and cytokine presence, similar to 
that of humans with BOS, was observed. Another group, from the University of Pittsburgh, 
has developed a human-mouse chimeric model of BOS in which the allograft and immune 
effector cells are of human origin. (Xue et al. 2011) They state that the formation of chimeric 
allogenic T cells, and the resulting infiltration into small human airways is definitive in 
delineating the role T cells play in the development of BOS. 
5.4.4.3 Future Therapeutics for Bronchiolitis Obliterans Syndrome 
This is, in part, a continuation of the previous section due to the experimental nature of 
some of the procedures/drugs described herein. As was previously discussed, there is an 
association of GER and BOS incidence. A study out of Duke University describes improved 
pulmonary function in patients who underwent proactive treatment for GER. Surgical 
fundoplication was performed to reduce the possibility of bile aspiration and potential 
damage to the airway. (Davis et al. 2003) Additionally, a retrospective study of transplant 
recipients with BOS identified a possible advantage of treatment with Azithromycin (Az), 
though the mechanism of action remains unclear. (Jain et al. 2010) Patients with a higher 
initial neutrophil burden responded better to the treatment and had better outcomes. What 
is most interesting is the fact that azithromycin is a macrolide antibiotic, a class known to be 
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inhibitors of matrix metalloproteinases. It is possible that Az is preventing the generation of 
PGP and thus relieving some of the neutrophil burden associated with BOS. 
A recent publication by our group in Science detailed a bi-functional enzyme, Leukotriene 
A4 Hydrolase (LTA4H), which serves to degrade PGP endogenously. This enzyme is 
present in both neutrophils and airway epithelium and is elevated in a mouse model of 
pulmonary infection and inflammation. (Snelgrove et al. 2010) Modulation of the activity of 
this important enzyme may provide a welcome opportunity to utilize patients’ own biology 
to help resolve some of the destructive chronic neutrophilic inflammation seen in BOS. We 
have also described two specific inhibitors of PGP, arginine-threonine-arginine (RTR), and 
an all “D” isomer of PGP (DD-PGP) that are potent in preventing the mechanism of action of 
PGP in vitro and in vivo. (Jackson et al. 2011; van Houwelingen et al. 2008) 
6. Conclusion 
Even though long-term survival of lung transplant recipients has improved over time, the 
overall mortality rate in lung transplantation remains significantly higher than any other 
whole organ transplant population. The relatively recent advent of a more appropriate 
organ allocation system, along with improved ability to preserve donor organs has 
increased the pool of available organs to all-time highs. Even so, the number of actual lungs 
harvested each year compared to the estimated viable donor lungs is a small fraction of 
what is possible. With continued advancement in animal models, and description of 
biomarkers of the various complications associated with transplantation, there has been 
marked, if gradual, improvements in the therapeutic armament clinicians have at their 
disposal. It may yet be that lung transplantation one day be viewed as an early intervention 
in progressive irreversible pulmonary conditions such as idiopathic pulmonary fibrosis and 
confer a permanent, rejuvenative improvement in the lifespan and quality of life of such 
patients. 
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respiratory disorders, and a variety of other conditions are also discussed. The book will be invaluable to
clinicians who keep up with the current concepts, improve their diagnostic skills, and understand potential new
therapeutic applications in lung diseases, while scientists can contemplate a plethora of new research avenues
for exploration.
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